RED: NICE TA893 - Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over. (Decision date - July 2023)
Red Drug Classifications
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
